Business
QuidelOrtho Reports First Quarter 2025 Financial Results
― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on
About this update from Quidelortho Corporation
[{"type":"text","content":"\n― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ―\n― Strong execution on cost-savings initiatives driving improved margins and profitability ―\n― Company maintains full-year 2025 financial guidance ―\n\nFirst Quarter 2025 Results\n(all comparisons are to the prior year period)\n\n\nTotal revenue was $693 million, as reported\n\n\nNon-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency\n\n\nLabs revenue grew 5% as reported and 7% in constant currency\n\n\nDonor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of that business\n\n\n\n\nRespiratory revenue was $120 million; excluding COVID-19, respiratory revenue grew 11% as reported and in constant currency\n\n\n\n\nGAAP operating expenses1 of $240 million decreased by $24 million or 9%; non-GAAP operating expenses of $233 million decreased by $18 million or 7%, both driven by the Company’s cost-saving initiatives\n\n\nGAAP operating margin increased from (247%) to 5%; adjusted EBITDA margin was 23%, an increase of 450 basis points\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nQuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 30, 2025.\n\n“We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. “Our ongoing operational improvement initiatives contributed meaningfully to our results. We are proactively addressing macroenvironment operating challenges and maintaining our full-year 2025 financial guidance based on our current business outlook. As we look ahead, we remain committed to commercial excellence, margin expansion, and supporting our customers and the patients who rely on our products.”\n\nFirst Quarter 2025\n\nThe Company reported total revenue for the first quarter of 2025 of $693 million, compared to $711 million in the prior year period. The decrease in total revenue was primarily due to lower COV...